VFA
TVRD

Virtus Fund Advisers’s Tvardi Therapeutics TVRD Stock Holding History

Virtus Fund Advisers’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$338K Buy
+768
New +$350K ﹤0.01% 424
2014
Q3 		– Sell
-13
Closed -$8K – 1982
2014
Q2 		$8K Buy
+13
New +$7K ﹤0.01% 2799

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Virtus Fund Advisers's TVRD Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Tvardi Therapeutics (TVRD) in Q4 2017: 768 shares worth $338K. The stake represents ﹤0.01% of the portfolio and ranks #424 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in TVRD as recently as Q2 2014.

Virtus Fund Advisers first reported a position in TVRD in Q2 2014 and has held it in 2 quarters since. 127 funds tracked by Wall St. Rank hold TVRD as of Q4 2017.

  • Virtus Fund Advisers held 768 shares of Tvardi Therapeutics worth $338K as of Q4 2017.
  • Tvardi Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Tvardi Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #424 holding.
  • Virtus Fund Advisers first reported a position in Tvardi Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 127 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.